Form 4: Arcutis Biotherapeutics Director Sells Shares

Sentiment:

Insider Transaction (Form 4)


Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc., sold 4,730 shares of common stock on August 17, 2026 for $26.18 per share.

Summary

  • Option exercise/conversion: acquired 822 Common Stock at $6.52 ($5,361) on August 17, 2026; holds 37,931 after (Direct).
  • Option exercise/conversion: acquired 1,019 Common Stock at $7.51 ($7,653) on August 17, 2026; holds 38,950 after (Direct).
  • Option exercise/conversion: acquired 2,255 Common Stock at $8.63 ($19,461) on August 17, 2026; holds 41,205 after (Direct).
  • Open-market sale: disposed of 4,730 Common Stock at $26.18 ($123,835) on August 17, 2026; holds 36,475 after (Direct).
  • Option exercise/conversion: disposed of 822 Stock Option (right to buy) on August 17, 2026; holds 7,396 after (Direct).
  • Option exercise/conversion: disposed of 1,019 Stock Option (right to buy) on August 17, 2026; holds 9,163 after (Direct).
  • Option exercise/conversion: disposed of 2,255 Stock Option (right to buy) on August 17, 2026; holds 20,287 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $123,835 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Howard G. Welgus — Director

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-17Option exercise/conversionCommon Stock822$7$5.4K37,931
2026-08-17Option exercise/conversionCommon Stock1,019$8$7.7K38,950
2026-08-17Option exercise/conversionCommon Stock2,255$9$19.5K41,205
2026-08-17Open-market saleCommon Stock4,730$26$123.8K36,475
2026-08-17Option exercise/conversionStock Option (right to buy)822——7,396
2026-08-17Option exercise/conversionStock Option (right to buy)1,019——9,163
2026-08-17Option exercise/conversionStock Option (right to buy)2,255——20,287

Key Dates

DateDescription
2026-08-17Option exercise/conversion (822 shares)
2026-08-17Option exercise/conversion (1,019 shares)
2026-08-17Option exercise/conversion (2,255 shares)
2026-08-17Open-market sale (4,730 shares)
2026-08-17Option exercise/conversion (822 shares)
2026-08-17Option exercise/conversion (1,019 shares)
2026-08-17Option exercise/conversion (2,255 shares)

Keywords

insider transaction, Form 4, ARQT, Arcutis Biotherapeutics, Inc., bearish, Howard G. Welgus

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.